The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer.
Louis Fehrenbacher
No relevant relationships to disclose
Jong-Hyeon Jeong
No relevant relationships to disclose
Priya Rastogi
No relevant relationships to disclose
Charles E. Geyer
No relevant relationships to disclose
Soonmyung Paik
Research Funding - GlaxoSmithKline
Patricia A. Ganz
No relevant relationships to disclose
Stephanie R. Land
No relevant relationships to disclose
Joseph P. Costantino
No relevant relationships to disclose
Sandra M. Swain
Consultant or Advisory Role - Nektar (U); Novartis (U); Roche/Genentech (U); Sanofi (U)
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech; Sanofi
Other Remuneration - Sanofi
Eleftherios P Mamounas
No relevant relationships to disclose
Norman Wolmark
Consultant or Advisory Role - Roche/Genentech (U)